2020
DOI: 10.3390/ph13080174
|View full text |Cite
|
Sign up to set email alerts
|

Receptors and Channels Possibly Mediating the Effects of Phytocannabinoids on Seizures and Epilepsy

Abstract: Epilepsy contributes to approximately 1% of the global disease burden. By affecting especially young children as well as older persons of all social and racial variety, epilepsy is a present disorder worldwide. Currently, only 65% of epileptic patients can be successfully treated with antiepileptic drugs. For this reason, alternative medicine receives more attention. Cannabis has been cultivated for over 6000 years to treat pain and insomnia and used since the 19th century to suppress epileptic seizures. The t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
22
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 39 publications
(32 citation statements)
references
References 180 publications
0
22
0
Order By: Relevance
“…A definitive pharmacological target for CBD in epilepsy (and elsewhere) remains elusive, with various reports of pharmacologically relevant affinity at several molecular targets (Gray & Whalley, 2020; Senn, Cannazza, & Biagini, 2020). The best recognised targets include transient receptor potential vanilloid channels and GPCR 18 (GPR18) and GPR55 receptors (Alexander et al, 2019).…”
Section: Cbd Mechanism Of Actionmentioning
confidence: 99%
See 1 more Smart Citation
“…A definitive pharmacological target for CBD in epilepsy (and elsewhere) remains elusive, with various reports of pharmacologically relevant affinity at several molecular targets (Gray & Whalley, 2020; Senn, Cannazza, & Biagini, 2020). The best recognised targets include transient receptor potential vanilloid channels and GPCR 18 (GPR18) and GPR55 receptors (Alexander et al, 2019).…”
Section: Cbd Mechanism Of Actionmentioning
confidence: 99%
“…And, the FDA is committed to this kind of careful scientific research and drug development. "3 | CBD MECHANISM OF ACTIONA definitive pharmacological target for CBD in epilepsy (and elsewhere) remains elusive, with various reports of pharmacologically relevant affinity at several molecular targetsSenn, Cannazza, & Biagini, 2020). The best recognised targets include transient receptor potential vanilloid channels and GPCR 18 (GPR18)…”
mentioning
confidence: 99%
“…The endocannabinoid system (ECS) is involved in regulation of excitatory and inhibitory synaptic transmission in the brain [65,66], and consists of two G protein-coupled receptors, CB 1 R and CB 2 R, with two known endogenous cannabinoid ligands, namely 2arachidonoylglycerol (2-AG) and N-arachidonoylethanolamide (NAN), respectively [10,11].…”
Section: Endocannabinoid Systemmentioning
confidence: 99%
“…In addition, glycerophosphodiesterase 3 can metabolize GPR55 ligand, arachidonoyl lysophosphatidylinositol (LPI), into 2-AG and also act as a signaling switch between GPR55 and CB2, thereby linking GRP55 to canonical cannabinoid receptors [187,188]. Moreover, neurological studies indicate that exogenous cannabinoids (i.e., CBD) also act on other noncanonical cannabinoid-sensitive receptors, such as transient receptor potential vanilloid 1 and opioid receptor µ and δ [189], that may be of interest in peripheral tissues. With respect to metabolic syndrome, emerging data suggest that GPR55 and LPIs are associated with obesity and adipogenesis [190].…”
Section: Other Receptors That Are Targeted By Cannabinoidsmentioning
confidence: 99%